ClinicalTrials.gg

Program

elraglusib

Also written as “9-ING-41” and “Elraglusib Oral Tablets”.

Its studies are mostly in Neoplasms · Primary Myelofibrosis · Salivary Gland Neoplasms, led by Actuate Therapeutics.

Furthest: phase 2, since Sep 15, 20185 company-led studies, 2 open or runningNext primary completion: Jul 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Actuate Therapeutics52 open or runningphase 2since Sep 15, 2018Sep 15, 2018Jul 2029phase 2 · NCT07714395

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 15, 2018First study: phase 2 study in NeoplasmsFirst studyNCT03678883 · 350 enrolled · United States, Belgium, Canada and more
  2. Jan 2, 2020Phase 2 study in Primary MyelofibrosisNCT04218071 · 17 enrolled · United States
  3. Jan 20, 2020Phase 1 study in NeoplasmsNCT04239092 · 40 enrolled · United States
  4. Apr 2, 2021Phase 2 study in Salivary Gland NeoplasmsNCT04832438 · United States
  5. Jun 19, 2026Phase 2 study in Advanced Malignant Solid TumorNCT07714395 · 100 planned

Ahead

  1. Jul 2029Primary completion: phase 2 study in Advanced Malignant Solid TumorNCT07714395

TargetBeta

GSK3B →read by rule
“Glycogen synthase kinase-3 beta inhibitor”ChEMBL 37, by rule

Other programs on GSK3B

ProgramCompanyFurthest phaseStudies
Lithium CarbonateruleMerckphase 35

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07714395Advanced Malignant Solid Tumor2Not yet recruitingJul 2029100
NCT04832438Salivary Gland Neoplasms · United States2WithdrawnJun 18, 20330
NCT04239092Neoplasms · United States1TerminatedJul 7, 202540
NCT04218071Primary Myelofibrosis · United States2CompletedOct 13, 202217
NCT03678883Neoplasms · United States, Belgium, Canada and more2Active, not recruitingJun 2026350

How it is read

Names in the registry

  • “9-ING-41”, 4 entries
  • “Elraglusib Oral Tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.